The myeloid cells targeting therapeutics market is anticipated to grow at a significant pace, till 2

With the recent FDA approval of Tavenos™ for ANCA-associated vasculitis, myeloid cells have become an attractive target for pharmacological interventions, being developed for the treatment of various oncological disorders

London

Roots Analysis has announced the addition of “Myeloid Cell Targeting Therapeutics Market, 2021-2035” report to its list of offerings.

With ever increasing cancer burden, the focus of the research community has shifted towards the development of alternatives for the traditional anticancer therapies, such as myeloid cell targeting therapeutics. Myeloid cells, with their multifaceted functions and abundance in tumor microenvironment can be easily targeted and have emerged as novel therapeutic candidates for the treatment of several oncological disorders in combination with chemotherapy and radiotherapy.

To order this 150+ page report, which features 100+ figures and 5+ tables, please visit
https://www.rootsanalysis.com/reports/myeloid-cells-targeting-therapeutics-market.html

Key Market Insights

Presently, more than 100 drug candidates are being evaluated across different phases of development
Over 70% of the pipeline candidates are currently being evaluated in clinical stages; of these, more than 35 candidates are in phase I of their clinical trials. This is followed by 25% therapies being investigated in preclinical and discovery stages. It is worth highlighting that majority of the therapy candidates (53%) are biologics.

More than 380,000 patients have been enrolled in over 1,500 clinical trials, worldwide
Clinical research activity, in terms of number of trials registered, is reported to have increased over the last five years. Of the total number of trials, close to 65% have already been completed, while 22% are active and still recruiting patients.